阿普米司特在儿童中重度斑块状银屑病中的药代动力学与安全性:2期开放标签研究结果
该2期多中心开放标签研究纳入42例儿童中重度斑块状银屑病患者,评估阿普米司特按体重给药的药代动力学与安全性。结果显示儿童20mg每日两次或青少年20/30mg每日两次的暴露量与成人30mg每日两次相当,安全性总体与成人相似,青少年和儿童PASI评分分别改善68%和79%。
要点
- 按体重给予阿普米司特可使儿童和青少年暴露量与成人30mg每日两次相当
- 安全性与成人总体相似,多数受试者喜欢片剂味道
- 青少年和儿童PASI评分较基线分别改善68%和79%
核心结论
- 本首次在儿童中开展的2期研究支持按体重给予阿普米司特,为未来儿童斑块状银屑病3期研究提供依据。
研究设计与样本
- 2期多中心开放标签研究,纳入42例中重度斑块状银屑病患儿(21例青少年12-17岁,21例儿童6-11岁)。
- 患者接受阿普米司特每日两次不滴定治疗2周,随后48周扩展期;主要终点为药代动力学和安全性。
主要发现
- 药代动力学建模和非房室分析显示,儿童20mg每日两次或青少年20/30mg每日两次的AUC0-12与成人30mg每日两次相当。
- 安全性特征与成人总体相似。
- 多数研究参与者喜欢片剂的味道。
- 青少年(总体)和儿童PASI评分较基线平均改善分别为68%和79%。
临床怎么用
- 儿童和青少年斑块状银屑病按体重给予阿普米司特可达到与成人30mg每日两次相当的暴露量。
局限性
- 未纳入体重低于20kg的儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No oral systemic treatments are approved for pediatric patients with psoriasis. OBJECTIVE: To evaluate the pharmacokinetics and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in pediatric patients with psoriasis. METHODS: This phase 2, multicenter, open-label study enrolled pediatric patients with moderate to severe plaque psoriasis. Patients received apremilast twice daily without titration for 2 weeks (group 1 [age, 12-17 years; weight, ≥35 kg]: apremilast 20 or 30 mg; group 2 [age, 6-11 years; weight, ≥15 kg]: apremilast 20 mg), followed by a 48-week extension. Primary endpoints were pharmacokinetics and safety. Other endpoints were taste/acceptability and change from baseline in score on the Psoriasis Area and Severity Index. RESULTS: A total of 42 enrolled patients (21 adolescents [age, 12-17 years] and 21 children [age, 6-11 years]) received apremilast. Pharmacokinetics modeling and noncompartmental analyses showed that weight-based dosing with apremilast 20 mg twice daily in children or apremilast 20 or 30 mg twice daily in adolescents provides exposure (area under the concentration-time curve from time 0 to 12 hours after the dose) that is comparable to that achieved with apremilast 30 mg twice daily in adults. The safety profile was generally similar to that in adults. Most study participants liked the taste of the tablet. Improvements from baseline in mean Psoriasis Area and Severity Index score were 68% for adolescents (overall) and 79% for children. LIMITATIONS: No children weighing less than 20 kg were enrolled. CONCLUSIONS: This first-time-in-children phase 2 study supports weight-based apremilast dosing for future phase 3 studies of pediatric plaque psoriasis.
引用
- Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. 2019. PMID: 31408686. doi:10.1016/j.jaad.2019.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。